Evotec & Bristol Myers Squibb Make Breakthrough in Neuroscience Collaboration

• Evotec announces progress in neuroscience collaboration with Bristol Myers Squibb - Scientific achievement triggers a research payment of US$ 20 m to Evotec - Target-based programme progresses into late pre-clinical development - Collaboration aims to identify disease-modifying treatments for neurodegenerative diseases - First programme in-licensed by Bristol Myers Squibb progresses to Phase II study - Evotec aims to create innovative therapeutics for patients suffering from neurological disorders

The next important date, Half-year report 2024 and webcast, at Evotec is on 14.08.2024.

The price of Evotec at the time of the news was 9,0000EUR and was up +1,78 % compared with the previous day.
17 minutes after the article was published, the price was 8,9500EUR this corresponds to a minus of -0,56 % since publication.
At this time, the index MDAX was at 26.488,54PKT (-1,04 %).

Evotec

+0,17 %

-3,40 %

-27,65 %

-30,88 %

-58,32 %

-78,81 %

-71,57 %

+55,51 %

+609,34 %

ISIN:DE0005664809WKN:566480

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• 3J
• 5J
• 10J
• Max